| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Par Pharmaceutical was founded in New York in 1978. Many products are
licensed-in from other generic manufacturers, such as Genpharm or Spectrum, or
originator companies. Par has concluded a number of authorised generic
agreements with originators, most recently with AstraZeneca for metoprolol ER.
Par's in-house manufacturing capabilities revolve principally around Kali
Laboratories, a company acquired in 2004. Both companies hold a number of
ANDAs under their own name. The most recent drug to be approved is
ondansetron, a version of Merck's Zofran.
The company boosted its position in the US market in 2006, through the
purchase of a number of drugs from Teva and IVAX. This was mandated by the FTC
as a condition of the merger between the latter two companies.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
Executive Summary
Introduction
Products
- Teva/IVAX Drugs Divested to Par Pharmaceutical Companies
- Par Pharmaceutical ANDA Approvals, 2002-06
- Kali Laboratories ANDA Approvals, 2004-06
- Recent Product Approvals
- Ondansetron
- Pravastatin
- Companies gain meloxicam approvals
- Orchid gains cephalexin ANDA approval
- Amlodipine besylate tablets (tentative)
- Tranylcypromine sulphate tablets
- Miralax generic
Financial results
- Par Pharmaceutical Financial Results 2001-05 (US$000s)
- Generic/Branded Revenues & Operating Income, 2003-05 (US$000s)
- Par Sales of Selected Generic Products, 2003-05 (US$000s)
Major Developments
- Mergers, acquisitions and agreements
- AstraZeneca/Par enter agreement for generic version of Toprol-XL
- Spectrum Pharmaceuticals
- Par divests FineTech
- Bradley and Par enter licensing agreement for Adoxa
- MN Pharmaceuticals
- Orchid Chemicals & Pharmaceuticals
- Litigation
- Reliant files patent infringement lawsuit against Par over Rythmol
- Unimed, Watson, Paddock and Par enter settlement agreements regarding
AndroGel litigation
Contact Details
|
